Targeting the MET pathway is an increasingly attractive anticancer strategy. In this Review, this pathway is viewed from the clinical perspective, assessing the available agents in terms of efficacy and toxicity and looking forward to biomarker-driven application in the clinic.
- Solange Peters
- Alex A. Adjei